Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 67M | 12.5% |
| Gross Profit | 66M | 1908.7% |
| Cost of Revenue | 1.4M | 97.5% |
| Operating expense | 161M | 37.5% |
| Net Income | -91M | 18.3% |
| EBITDA | -85M | 16.9% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 905M | 0.3% |
| Total Liabilities | 203M | 3% |
| Total Equity | 702M | 0.5% |
| Shares Outstanding | 364M | 8.8% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -79M | 16.7% |
| Cash from investing | 17M | 22.9% |
| Cash from financing | 88M | 565.6% |
EPS
Financial Highlights for Iovance Biotherapeutics in Q3 '25
Iovance Biotherapeutics reported a revenue of 67M, which is a 12.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 66M, marking a 1908.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 1.4M, a -97.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 161M, showing a 37.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -91M, showing a 18.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -85M, showing a 16.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Iovance Biotherapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
